A naturopathic cardiology perspective on advanced biomarkers, metabolic and hormonal health, continuous glucose monitoring, cardiovascular imaging, and emerging therapies for more individualized risk assessment and prevention.
| Clinical Premise: Contemporary cardiovascular risk evaluation increasingly incorporates plaque biology, inflammation, oxidation, metabolic variability, hormonal and thyroid status, and direct anatomic and physiologic imaging. The goal is not to replace evidence-based cardiology, but to individualize it. |
Introduction
Cardiovascular disease remains a leading cause of morbidity and mortality in men, yet the way clinicians assess and modify cardiovascular risk is changing. Conventional cardiology historically focused on blood pressure, smoking, diabetes, family history, and circulating lipid concentrations—particularly low-density lipoprotein cholesterol (LDL-C). These measures remain important, but they do not fully describe the biological processes that make an individual plaque vulnerable, inflamed, oxidized, thrombogenic, or likely to rupture.
A naturopathic cardiology perspective does not reject conventional risk reduction, rather, it expands the clinical question. In addition to asking how much atherogenic cholesterol is circulating, clinicians may wish to expand their models to find whether lipoproteins are being oxidized, whether the vascular wall is inflamed, whether glucose excursions are injuring the endothelium, whether endocrine abnormalities are amplifying risk, and whether advanced imaging demonstrates actual plaque or flow limitation.
Statins and aspirin illustrate both the success and limitations of conventional prevention. They remain valuable therapies in appropriately selected patients—especially in secondary prevention—but they are mature technologies developed before coronary CT angiography, CT-derived fractional flow reserve, continuous glucose monitoring, and modern cardiometabolic medications became available.
Statin Therapy: Benefits, Limitations, and the Plaque Paradox
Lovastatin, the first statin approved by the U.S. Food and Drug Administration, entered clinical use in 1987.[1] Statins inhibit HMG-CoA reductase, reduce hepatic cholesterol synthesis, and increase hepatic clearance of circulating LDL particles. Their ability to reduce major vascular events is supported by extensive randomized evidence, with absolute benefit greatest in patients who have established atherosclerotic cardiovascular disease or a high baseline risk.[2,3] An example of a patient who may be more likely to benefit would be a 50-year-old male, smoker, mild to moderate obesity, elevated HGB A1c to prediabetes or more, and is sedentary. (4-6 risk factors)
The clinical value of statin therapy should not, however, be interpreted by the numerical lowering of LDL-C. Statins also alter plaque composition and vascular biology. Imaging studies demonstrate slower soft plaque progression, and a shift toward denser calcification.[4–7] These changes support the concept that statins can convert a relatively soft, inflamed, rupture-prone plaque into a more stable phenotype in high-risk patients.
This phenomenon is sometimes described clinically as the plaque paradox. Coronary calcium scores may remain unchanged or increase during effective statin treatment because noncalcified plaque becomes more densely calcified. An increase in calcium density is therefore not automatically equivalent to treatment failure or accelerated plaque vulnerability.[4,6] Serial calcium scoring alone cannot distinguish all favorable from unfavorable changes in plaque composition; CCTA is better suited to that question.
Plaque stabilization and LDL/ApoB lowering should not be framed as competing explanations. The strongest evidence indicates that lowering exposure to atherogenic ApoB-containing particles may mildly reduce cardiovascular events, while the associated changes in inflammation, lipid content, fibrous-cap characteristics, and calcification help explain how that reduction is translated into a safer plaque phenotype.[2–7]
The evidence base is historically deepest in middle-aged men, because many foundational prevention and secondary-prevention trials enrolled disproportionately large numbers of men. Nevertheless, contemporary meta-analyses support proportional risk reduction in women as well. The major difference is often absolute benefit: a 45- to 65-year-old man with smoking, hypertension, diabetes, elevated ApoB, or documented plaque has more events available to prevent than a younger patient or a patient with few risk factors.[2,3,8]
In low-risk primary prevention, the expected absolute benefit may be modest to non-present, and should be weighed against patient preferences, competing risks, imaging findings, and treatment burden. This is particularly important when a risk calculator is driven primarily by age, but direct imaging shows little or no plaque.
- Potential adverse effects and clinical concerns: statin-associated muscle symptoms, myalgia, weakness, rare myopathy or rhabdomyolysis, elevation of hepatic enzymes, clinically relevant drug interactions, and a modest increase in new-onset type 2 diabetes among susceptible patients. Cognitive symptoms as well as increases in cancers such as breast are occasionally reported, but randomized and systematic-review data have not demonstrated a consistent adverse effect.[9,10]
Aspirin Therapy: A Mature Technology Requiring Careful Selection
Aspirin predates the modern FDA, but the FDA approved a cardiovascular indication for secondary prevention of recurrent myocardial infarction and death in patients with myocardial infarction or unstable angina in October 1985.[11] Aspirin irreversibly inhibits platelet cyclooxygenase-1, reducing thromboxane A2 formation and platelet aggregation.
Its clearest cardiovascular role is secondary prevention: patients with prior myocardial infarction, ischemic stroke, symptomatic coronary disease, or selected revascularization histories generally have sufficient thrombotic risk to justify antiplatelet therapy unless bleeding risk or another contraindication dominates.[12]
The case for routine aspirin in primary prevention has weakened. Contemporary trials and meta-analyses show that any reduction in nonfatal ischemic events may be offset by gastrointestinal or intracranial bleeding, particularly in older adults and patients with lower baseline cardiovascular risk.[13–16] Aspirin is therefore no longer a generic “heart-health” supplement; it is an antiplatelet drug whose net value depends on the balance between thrombosis and bleeding.
As with statins, earlier aspirin trials frequently included more men than women. The practical issue is again absolute risk rather than an assumption that women do not benefit; patients with fewer risk factors have fewer events to prevent, so even a similar relative effect produces a smaller absolute benefit while bleeding risk remains present.
- Potential adverse effects and clinical concerns: dyspepsia, gastritis, gastric or duodenal ulceration, gastrointestinal bleeding, hemorrhagic stroke or other intracranial bleeding, bruising, epistaxis, hypersensitivity reactions, aspirin-exacerbated respiratory disease, renal impairment in susceptible patients, anemia from occult blood loss, and interactions with anticoagulants, corticosteroids, alcohol, and other nonsteroidal anti-inflammatory drugs.[12–16]
Non-statin lipid-lowering therapies demonstrate that improving LDL-C does not always translate into an equally impressive reduction in cardiovascular events. Niacin is the clearest example, as it favorably changed LDL-C, triglycerides, and HDL-C but failed to improve outcomes when added to statin therapy and increased adverse effects. Ezetimibe, PCSK9 inhibitors, and bempedoic acid have shown statistically significant cardiovascular benefit, particularly in high-risk patients with established atherosclerotic disease, but their absolute risk reductions have generally been modest compared with the magnitude of LDL lowering. These findings do not make non-statin therapies ineffective; rather, they reinforce that cardiovascular risk is determined by more than a lipid number alone and includes inflammation, oxidation, thrombosis, plaque composition, metabolic dysfunction, and baseline disease burden.
“For the naturopathic cardiovascular clinician, the opportunity is not to choose between conventional cardiology and whole-person medicine. It is to combine the strongest elements of both: accurate diagnosis, evidence-based therapy, metabolic restoration, nutritional precision, and individualized prevention.”
Moving Beyond the Standard Lipid Panel
LDL-C, HDL-C, triglycerides, ApoB, and lipoprotein(a) remain central to cardiovascular assessment. ApoB approximates the number of circulating atherogenic particles, while Lp(a) identifies a highly heritable and frequently underrecognized risk. However, cholesterol quantity alone does not reveal whether lipoproteins have become oxidized, whether the vessel wall is inflamed, whether plaque-associated enzymes are active, or whether metabolic and endocrine signals are creating an environment that favors plaque progression.
Advanced biomarkers are not equally validated and should not be ordered indiscriminately. Some are established clinical measures, while others are best viewed as risk-enhancing, mechanistic, or hypothesis-generating markers. Their value is greatest when they answer a specific clinical question or reveal a coherent pattern.
Trimethylamine N-Oxide (TMAO)
TMAO is produced when intestinal microorganisms convert nutrients such as choline and carnitine (sourced generally from animal fat such as eggs, beef, pork, and certain fish products, into trimethylamine, which is then oxidized by the liver. Higher circulating TMAO has been associated with cardiovascular events and mortality, but kidney function, diet, medications, and microbiome composition materially influence the result, and causality remains debated.[17,18] It is best interpreted as a marker of the diet–microbiome–liver–kidney axis rather than as an isolated instruction to eliminate all choline- or carnitine-containing foods.
Hemoglobin A1c
Hemoglobin A1c estimates average glycemic exposure over approximately two to three months by measuring glycated hemoglobin. Cardiovascular risk rises well before diabetes is formally diagnosed, but A1c may miss postprandial spikes and glucose variability and can be distorted by anemia, hemoglobin variants, kidney disease, or altered red-cell turnover. It should be interpreted with fasting glucose, fasting insulin, triglycerides, waist circumference, and—when clinically useful—CGM data.
Ferritin
Ferritin is the major intracellular iron-storage protein and is commonly used as a surrogate for iron stores. Because it is also an acute-phase reactant, an elevated ferritin can reflect iron overload, inflammation, liver disease, metabolic dysfunction, infection, or several of these simultaneously. Both iron deficiency and excess may be clinically important; interpretation should include transferrin saturation, serum iron, total iron-binding capacity, CBC, liver enzymes, and inflammatory context.[19]
Total 25-Hydroxyvitamin D
Total 25-hydroxyvitamin D is the preferred test for vitamin D status. Low levels correlate observationally with hypertension, obesity, insulin resistance, inflammation, and cardiovascular events, but randomized trials have not shown that indiscriminate high-dose supplementation reliably prevents cardiovascular disease.[20,21] The clinical goal should be correction of true deficiency and restoration of physiological sufficiency—not pursuit of supraphysiologic concentrations. There is a question as to what the best levels are as the lab range may be from 20ng/ml-150 ng/ml. New data demonstrates that as the total moves past 70ng/ml, risk of arrythmia (atrial fibrillation) and other cardiovascular issues may increase.
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
Lp-PLA2 is an enzyme carried largely on LDL that acts on oxidized phospholipids and generates inflammatory products within the arterial wall. Higher mass or activity is associated with coronary and cerebrovascular risk, although part of that association is lipid-dependent and pharmacologic inhibition of Lp-PLA2 has not established it as a stand-alone therapeutic target.[22,23]
Myeloperoxidase (MPO)
MPO is an oxidative enzyme released primarily by activated neutrophils and monocytes. It generates reactive oxidant species that can impair endothelial function and modify both LDL and HDL, linking innate immune activation to plaque vulnerability.[24] MPO is not specific to coronary disease and may rise with infection or systemic inflammation; it is best interpreted with symptoms, hs-CRP, oxidized lipoproteins, renal function, and imaging.
Oxidized LDL
Oxidized LDL represents LDL particles chemically modified within an oxidative and inflammatory environment. OxLDL promotes endothelial dysfunction, macrophage uptake, foam-cell formation, and pro-inflammatory signaling.[25] An elevated result suggests that the issue is not only particle quantity but particle modification; smoking, dysglycemia, visceral adiposity, systemic inflammation, and overall ApoB burden should be assessed concurrently.
Oxidized or Dysfunctional HDL
HDL concentration does not necessarily equal HDL function. Under inflammatory and oxidative conditions, HDL can lose antioxidant, anti-inflammatory, and cholesterol-efflux capacity and become dysfunctional.[26] This helps explain why a high HDL-C value does not guarantee protection and may increase overall risk.
Homocysteine
Homocysteine is a sulfur-containing intermediate in methionine metabolism. It may rise with folate, B12, B6, riboflavin, or choline insufficiency; renal dysfunction; hypothyroidism; smoking; alcohol use; genetics; or medications. Elevated levels are associated with endothelial dysfunction and thrombotic risk, but B-vitamin therapy (usually given as co-factored B vitamins) lowers homocysteine consistently. [27,28]
Estradiol
In men, estradiol is produced largely through aromatization of testosterone in adipose and other tissues. Elevated estrogens including estradiol can increase risk of embolization, thrombosis, hypertension, and fluid retention. Cardiovascular associations are complex; estradiol should be interpreted with testosterone, SHBG, adiposity, liver function, symptoms, aromatase-inhibitor use.
Estrone
Estrone is a weaker estrogen formed in peripheral tissues, particularly adipose tissue. Elevated estrone may accompany visceral obesity, insulin resistance, increased aromatization, alcohol exposure, or liver dysfunction. Evidence linking estrone directly to cardiovascular outcomes in men is limited, so it is best treated as a contextual endocrine marker rather than an independent cardiovascular risk diagnosis. It is possible that as Estrone levels increase beyond expected ranges, that cardiovascular risk may coordinately increase as well.
Testosterone
Low endogenous testosterone is associated with obesity, metabolic syndrome, diabetes, reduced muscle mass, inflammation, and higher cardiovascular risk, although it may be both a contributor to and a marker of chronic illness. Diagnosis requires symptoms plus appropriately obtained morning measurements, often repeated and interpreted with free testosterone, estrogens, hematocrit, and prostate considerations. In TRAVERSE, testosterone therapy was noninferior to placebo for major adverse cardiovascular events in appropriately selected hypogonadal men at elevated cardiovascular risk, but monitoring remains essential.[29]
Thyroid Panel
A cardiovascular thyroid assessment generally begins with TSH and free T4, with free T3 and thyroid antibodies added when clinically indicated. Hypothyroidism can lead to increases in diastolic pressure, weight, and vascular stiffness; while hyperthyroidism can provoke tachycardia, atrial fibrillation, increased myocardial oxygen demand, and muscle loss.[30] Even subclinical abnormalities may be important in older adults and patients with arrhythmia.
Summary: From Lipid Numbers to Plaque Biology
The emerging model is not “lipids versus inflammation.” LDL-C, ApoB, and Lp(a) describe essential aspects of atherogenic exposure; inflammatory, oxidative, metabolic, endocrine, and thrombotic markers help explain how that exposure is being expressed in a particular patient. The practical objective is not to order every advanced test, but to identify the mechanism that remains active despite apparently acceptable standard numbers.
A man with premature coronary disease despite modest LDL-C may benefit from ApoB, Lp(a), glycemic assessment, selected inflammatory and oxidative markers, and direct plaque imaging. A man with atrial fibrillation, visceral obesity, sleep apnea, and borderline A1c may require more attention to glucose variability, thyroid status, androgen–estrogen balance, and body composition than to total cholesterol alone.
Continuous Glucose Monitoring in Cardiovascular Patients
Continuous glucose monitors provide information that fasting glucose and A1c cannot: postprandial excursions, nocturnal patterns, time above range, and glycemic variability. These data can reveal individualized responses to food, exercise, sleep loss, stress, alcohol, and medication.
Repeated glucose excursions are biologically linked to oxidative stress, endothelial dysfunction, sympathetic activation, and inflammation. CGM is established in diabetes management, but routine use in every nondiabetic cardiac patient—including every arrhythmia patient—has not yet been validated by outcomes trials.[31] A scientifically defensible position is that short-term CGM can be a valuable phenotyping and educational tool in selected patients with prediabetes, obesity, metabolic syndrome, unexplained glucose variability, or symptoms and rhythm changes that appear meal-related.
GLP-1–Based Therapy: Beyond Weight Loss
GLP-1 receptor agonists and related incretin-based therapies improve satiety, reduce caloric intake, improve glycemic control, and produce clinically meaningful weight loss. Their cardiovascular relevance extends beyond the scale because visceral adipose tissue is metabolically active and promotes insulin resistance, inflammation, sleep apnea, hypertension, and increased cardiac workload.
The statement that each pound of fat requires approximately five to seven miles of additional blood vessels is a useful educational metaphor but should not be presented as a precise, universally measured anatomical constant. A safer formulation is that expanding adipose tissue requires substantial microvascular growth and increases circulatory and metabolic demand.
In SELECT, semaglutide reduced major adverse cardiovascular events by approximately 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[32,33] The benefit cannot be attributed to weight loss alone with certainty; improvements in blood pressure, glycemia, inflammation, renal risk, and other pathways are likely contributors.
Early imaging and mechanistic studies suggest favorable effects on atherosclerotic biology, but direct coronary plaque regression should still be described as emerging rather than universally established. The strongest present claim is reduction in cardiovascular events in defined high-risk populations, accompanied by substantial weight loss and improved cardiometabolic risk.
- Potential adverse effects and clinical concerns: nausea, vomiting, diarrhea, constipation, gallbladder disease, dehydration, possible worsening of gastroparesis, loss of lean mass during rapid weight reduction, cost and access barriers, and weight regain after discontinuation. Adequate protein intake, resistance exercise, hydration, and preservation of muscle mass should be integral to treatment.
Better Imaging, Medications, Devices, and Procedures
Contrast-enhanced coronary CT angiography can identify calcified and noncalcified plaque, define plaque distribution and morphology, and identify high-risk features. Fractional flow reserve derived from CCTA—or invasive FFR when appropriate—adds functional information by estimating whether a coronary lesion restricts blood flow.[34,35] This combination moves assessment beyond a binary stress-test result or a calcium score alone.
Pharmacology has also expanded. Sacubitril/valsartan reduced cardiovascular death and heart-failure hospitalization compared with enalapril in patients with heart failure and reduced ejection fraction.[36] GLP-1–based therapies, SGLT2 inhibitors, and other targeted medications allow clinicians to address mechanisms beyond a basic cholesterol number.
Device and structural-heart therapy continue to evolve. Cardiac resynchronization therapy improves ventricular coordination and outcomes in appropriately selected patients with systolic heart failure and electrical dyssynchrony.[37] Transcatheter aortic-valve replacement has transformed the treatment of severe aortic stenosis by offering an effective, less invasive alternative to open surgery for a broad range of appropriately selected patients.[38]
These advances do not eliminate the importance of nutrition, exercise, sleep, smoking cessation, stress regulation, and carefully selected supplementation. Rather, they make genuine personalization possible: treatment can be shaped by plaque burden, coronary physiology, metabolic response, rhythm behavior, ventricular function, nutritional status, and patient preference.
Conclusion
Statins and aspirin remain valuable therapies, particularly in secondary prevention and in patients whose baseline cardiovascular risk clearly exceeds treatment risk, however, they may be dated technologies when compared to more individually precise model of expanded risk factor analysis being paired with specific treatment.
Between better diagnostic technologies such as contrast-enhanced CCTA and fractional flow reserve, more comprehensive cardiometabolic medications such as GLP-1 receptor agonists and sacubitril/valsartan, advanced pacing and resynchronization, less invasive procedures such as TAVR, and focused nutritional, supplemental, and lifestyle interventions, this may be the most capable period in the history of cardiovascular medicine.
For the naturopathic cardiovascular clinician, the opportunity is not to choose between conventional cardiology and whole-person medicine. It is to combine the strongest elements of both: accurate diagnosis, evidence-based therapy, metabolic restoration, nutritional precision, and individualized prevention.
Acknowledgment: The author acknowledges the editorial and research assistance of “Vector,” an OpenAI language model, in organizing the manuscript, refining the discussion, and identifying supporting literature. All clinical opinions, interpretations, and final editorial decisions remain those of the author.
